Clinical Trial Update: Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) [Phase 4]

View source ↗

Summary

Phase 4 pilot study assessing the CHOP-daclizumab combination (CHOP-Zenapax) for HTLV-I-associated adult T-cell leukemia/lymphoma; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Leukemia Lymphoma

Drugs mentioned

• CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
• Zenapax (daclizumab)

Snippet

Sponsor: King's College Hospital NHS Trust | Conditions: HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL) | Phase 4 | Status: COMPLETED